Print

AVEG 007C

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200micrograms SF-2 gp120 Protein with MF59 Emulsion

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) November 16, 1992
rgp120/HIV-1 SF-2 Env gp120 B SF-2
rgp120/HIV-1 SF-2 Protein
MF59
USA 14
NCT00000749
https://clinicaltrials.gov/show/NCT00000749